Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free AADI Stock Alerts

Aadi Bioscience (AADI) Competitors

Aadi Bioscience logo
$3.99 -0.02 (-0.50%)
As of 05/1/2026
Compare

AADI vs. NAGE, SNDL, AGMB, ENTA, and AVTX

Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Niagen Bioscience (NAGE), SNDL (SNDL), AgomAb Therapeutics (AGMB), Enanta Pharmaceuticals (ENTA), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry.

How does Aadi Bioscience compare to Niagen Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Niagen Bioscience has a consensus price target of $15.00, suggesting a potential upside of 210.88%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Aadi Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Niagen Bioscience
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Niagen Bioscience has a net margin of 13.43% compared to Aadi Bioscience's net margin of -246.06%. Niagen Bioscience's return on equity of 21.10% beat Aadi Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Aadi Bioscience-246.06% -71.87% -57.28%
Niagen Bioscience 13.43%21.10%14.92%

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aadi Bioscience and Aadi Bioscience both had 1 articles in the media. Aadi Bioscience's average media sentiment score of 0.00 equaled Niagen Bioscience'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aadi Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Niagen Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Niagen Bioscience has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aadi Bioscience$25.07M3.93-$65.76M-$2.35N/A
Niagen Bioscience$129.42M2.99$17.38M$0.2024.13

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500.

Summary

Niagen Bioscience beats Aadi Bioscience on 11 of the 14 factors compared between the two stocks.

How does Aadi Bioscience compare to SNDL?

Aadi Bioscience (NASDAQ:AADI) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

SNDL has a net margin of -1.19% compared to Aadi Bioscience's net margin of -246.06%. SNDL's return on equity of -1.02% beat Aadi Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Aadi Bioscience-246.06% -71.87% -57.28%
SNDL -1.19%-1.02%-0.85%

SNDL has a consensus price target of $5.00, suggesting a potential upside of 246.02%. Given SNDL's stronger consensus rating and higher possible upside, analysts plainly believe SNDL is more favorable than Aadi Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
SNDL
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, SNDL had 16 more articles in the media than Aadi Bioscience. MarketBeat recorded 17 mentions for SNDL and 1 mentions for Aadi Bioscience. SNDL's average media sentiment score of 0.22 beat Aadi Bioscience's score of 0.00 indicating that SNDL is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aadi Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SNDL
2 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, SNDL has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

SNDL has higher revenue and earnings than Aadi Bioscience. SNDL is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aadi Bioscience$25.07M3.93-$65.76M-$2.35N/A
SNDL$677.32M0.55-$11.29M-$0.03N/A

Summary

SNDL beats Aadi Bioscience on 12 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to AgomAb Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

AgomAb Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. AgomAb Therapeutics' return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Aadi Bioscience-246.06% -71.87% -57.28%
AgomAb Therapeutics N/A N/A N/A

AgomAb Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 156.00%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Aadi Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, Aadi Bioscience and Aadi Bioscience both had 1 articles in the media. Aadi Bioscience's average media sentiment score of 0.00 equaled AgomAb Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aadi Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AgomAb Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AgomAb Therapeutics has lower revenue, but higher earnings than Aadi Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aadi Bioscience$25.07M3.93-$65.76M-$2.35N/A
AgomAb TherapeuticsN/AN/AN/AN/AN/A

Summary

AgomAb Therapeutics beats Aadi Bioscience on 6 of the 9 factors compared between the two stocks.

How does Aadi Bioscience compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Enanta Pharmaceuticals currently has a consensus price target of $20.29, indicating a potential upside of 39.83%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Enanta Pharmaceuticals is more favorable than Aadi Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Enanta Pharmaceuticals has a net margin of -106.80% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Enanta Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals-106.80% -78.58% -23.18%
Aadi Bioscience -246.06%-71.87%-57.28%

In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 1 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.69 beat Aadi Bioscience's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enanta Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aadi Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aadi Bioscience has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$66.98M6.29-$81.89M-$3.20N/A
Aadi Bioscience$25.07M3.93-$65.76M-$2.35N/A

Enanta Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Summary

Enanta Pharmaceuticals beats Aadi Bioscience on 10 of the 15 factors compared between the two stocks.

How does Aadi Bioscience compare to Avalo Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Aadi Bioscience has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aadi Bioscience$25.07M3.93-$65.76M-$2.35N/A
Avalo Therapeutics$60K7,229.51-$78.26M-$5.73N/A

In the previous week, Avalo Therapeutics had 10 more articles in the media than Aadi Bioscience. MarketBeat recorded 11 mentions for Avalo Therapeutics and 1 mentions for Aadi Bioscience. Avalo Therapeutics' average media sentiment score of 0.56 beat Aadi Bioscience's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aadi Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avalo Therapeutics
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Avalo Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Avalo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aadi Bioscience-246.06% -71.87% -57.28%
Avalo Therapeutics N/A -77.91%-61.78%

Avalo Therapeutics has a consensus price target of $44.83, indicating a potential upside of 176.07%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Aadi Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Avalo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Avalo Therapeutics beats Aadi Bioscience on 10 of the 17 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AADI vs. The Competition

Export
MetricAadi BiosciencePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$98.54M$892.30M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio-1.751.7229.0328.47
Price / Sales3.93120.12476.1060.92
Price / CashN/A20.0727.6236.52
Price / Book0.937.609.676.67
Net Income-$65.76M-$4.80M$3.55B$332.53M
7 Day Performance-0.99%0.09%1.75%2.03%
1 Month Performance13.68%5.64%5.66%9.23%
1 Year Performance131.30%30.92%34.42%39.62%

Aadi Bioscience Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AADI
Aadi Bioscience
N/A$3.99
-0.5%		N/AN/A$98.54M$25.07MN/A40
NAGE
Niagen Bioscience
3.3065 of 5 stars		$4.84
-2.4%		$16.00
+230.6%		N/A$397.20M$129.42M24.20120
SNDL
SNDL
3.0689 of 5 stars		$1.47
-2.6%		$5.00
+240.1%		N/A$388.67M$677.32MN/A2,751
AGMB
AgomAb Therapeutics
N/A$10.64
-6.0%		$32.00
+200.8%		N/A$385.56MN/AN/A62
ENTA
Enanta Pharmaceuticals
2.184 of 5 stars		$13.71
+3.2%		$20.29
+48.0%		N/A$385.38M$65.32MN/A160

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel